Jabbour Jerome D 4
4 · Matinas BioPharma Holdings, Inc. · Filed May 2, 2025
Insider Transaction Report
Form 4
Jabbour Jerome D
DirectorPresident and CEO
Transactions
- Award
Stock Option (right to Buy)
2025-04-30+70,100→ 70,100 totalExercise: $0.59Exp: 2035-04-30→ Common Stock (70,100 underlying)
Footnotes (1)
- [F1]The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. The options vest, subject to stockholder approval of the 2025 Plan, as to 25% of the shares on April 30, 2026 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing April 30, 2026.